close
close

AbbVie signs agreement to acquire Aliada for $1.4 billion.

Posted on by L. Dreeye
AbbVie signs agreement to acquire Aliada for .4 billion.

The acquisition will include Aliada’s ALIA-1758, which is in development to treat Alzheimer’s disease. Photo: Art_Photo/Shutterstock.

AbbVie has entered into a definitive agreement to acquire all of the outstanding shares of Aliada Therapeutics for $1.4 billion in cash.

The deal will include Aliada’s lead investigational product, ALIA-1758, which is in development for the treatment of Alzheimer’s disease.

Aliada is at the forefront of developing treatments using blood-brain barrier (BBB) ​​crossing technology that targets transferrin and CD98 receptors, which are abundant in brain endothelial cells.

This technology is an integral part of the modular delivery platform (MODEL), designed to precisely deliver drugs to the central nervous system.

ALIA-1758 uses this technology to transport anti-amyloid beta pyroglutamate antibodies across the BBB to disrupt beta-amyloid plaques associated with Alzheimer’s disease.

The MODEL platform, originally developed by Johnson & Johnson (J&J) scientists, is designed to deliver biological cargo to the brain.

Access the most comprehensive company profiles in the market, courtesy of GlobalData. Save hours of research. Gain a competitive advantage.

Company Profile – Free Sample

Your download email will arrive shortly.

We are confident in the unique quality of our company’s profiles. However, we want you to make the best decision for your business, so we offer a free sample that you can download by submitting the form below.

Author GlobalData







Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can unsubscribe from future marketing messages. Our services are intended for business subscribers and you warrant that the email address provided is your business email address.

These include therapeutic antibodies and genetic drugs such as small interfering RNA.

The acquisition of AbbVie is expected to strengthen the company’s research and development capabilities, accelerating the development of new treatments for neurological disorders.

AbbVie Executive Vice President and Chief Scientific Officer of Research and Development Rupal Thakkar said, “Neuroscience is one of our key growth areas, and we are committed to driving innovation in this area to address the critical unmet needs of patients living with serious, debilitating neurological diseases such as like Alzheimer’s disease. .

“This acquisition immediately gives us the opportunity to advance ALIA-1758, a potentially best-in-class Alzheimer’s disease-modifying therapy.”

ALIA-1758 is currently undergoing phase I clinical trials to evaluate its tolerability and safety in healthy participants.

The transaction, subject to regulatory approvals and customary closing conditions, is expected to close in the fourth quarter of 2024.

Covington & Burling advised AbbVie on the transaction, Centerview Partners provided financial advice, and Fenwick & West provided legal advisory services to Aliada.

AbbVie recently collaborated with Gedeon Richter to develop new treatments for neuropsychiatric diseases.